46 results about "Bacterial outer membrane vesicles" patented technology

The invention provides a bacterial outer membrane vesicle presenting Stoppin peptide as well as a construction method and application of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. According to the invention, a fusion protein ClyA-Stoppin is firstly designed and synthesized, and the fusion protein ClyA-Stoppin is displayed on the surface of the bacterial outer membrane vesicle by using a genetic engineering technology, so that the engineered bacterial outer membrane vesicle W-Stoppin OMV for targeting presentation of Stoppin peptide is successfully constructed. The W-Stoppin OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells and can be used for remarkably promoting apoptosis of the tumor cells. According to the present invention, with the Stoppin monopeptide, the problems of insufficient Stoppin cell penetrability and difficult intracellular delivery are effectively solved, compared with the Stoppin monopeptide, the Stoppin monopeptide shows the excellent anti-tumor effect, and the migration inhibition, the invasion inhibition and the apoptosis promotion effects on the tumor cells are significantly increased. The W-Stoppin OMV provided by the invention has huge application potential in the aspect of preparation of anti-tumor drugs.

A plasmid capable of automatically inserting a membrane-localized luciferase reporter gene into a chromosome of a bacterium / recipient bacterium. After the plasmid inserts a luciferase reporter gene into a chromosome of a bacterium / recipient bacterium, the plasmid can be lost. Since the plasmid can be lost, the bacterium / recipient bacterium into whose chromosome the luciferase reporter gene is inserted does not require the addition of antibiotics during subsequent use, providing convenience and reducing interference.

The invention provides a bacterial outer membrane vesicle drug carrier with a targeting effect and preparation, and relates to the technical field of biological medicines.The bacterial outer membrane vesicle protein ClyA derived from an escherichia coli W3110 strain is combined with iRGD protein capable of being combined with an integrin receptor alpha v beta 3, a ClyA-iRGD-pGEX-6P-1 recombinant plasmid for expressing ClyA-iRGD fusion protein is constructed, and the ClyA-iRGD-pGEX-6P-1 recombinant plasmid is used for preparing the bacterial outer membrane vesicle drug carrier with the targeting effect. By endogenous expression of the plasmid in W3110 escherichia coli, the C-iRGD-OMVs which has a tumor targeting effect and shows ClyA-iRGD fusion protein on the surface is prepared. The C-iRGD-OMVs shows efficient targeting binding capacity to MCF-7 breast cancer cells, overcomes the defect that iRGD single peptide is prone to aggregation and crystallization, has the potential of loading drugs, lays a foundation for the C-iRGD-OMVs serving as a targeting carrier for delivering breast cancer treatment drugs, and is expected to be further developed into a targeting treatment preparation for breast cancer.

The application provides a kind of bacterial outer membrane vesicle based on acid-sensitive peptide label and its preparation method and application, it is related to the technical field of engineered bacterial outer membrane vesicle.The ClyA-pHLIP fusion protein is designed and synthesized in the application, and the pHA-W3110OMV stably expressing the ClyA-pHLIP fusion protein is successfully obtained by using genetic engineering technology.The pHA-W3110OMV effectively solves the problem of easy aggregation of pHLIP in acidic environment, has good stability and solubility, and provides conditions for the stable targeting performance of pHLIP.Meanwhile, the pHA-W3110OMV not only retains the characteristics of targeting tumor cells in acidic environment, but also realizes the characteristics of targeting tumor cells in non-acidic environment.The pHA-W3110OMV has high targeting tracing efficiency on tumor cells under different pH conditions, and can realize qualitative and quantitative detection of tumor cells in peripheral blood, and has application potential in circulating tumor cell detection and tumor primary and metastasis localization.

The invention provides an anti-tumor peptide modified bacterial outer membrane vesicle and a preparation method thereof, and relates to the technical field of engineering bacterial outer membrane vesicles. According to the invention, a recombinant plasmid capable of expressing a ClyA-A25 fusion protein in a prokaryote is designed and constructed, and the engineering bacterium outer membrane vesicle W-A25OMV modified by the anti-tumor peptide A25 is successfully prepared by using the recombinant plasmid. The W-A25OMV retains the basic structure of bacterial outer membrane vesicles, enhances the anti-tumor biological activity of A25 peptide, has good stability, shows a remarkable inhibition effect on invasion and migration of tumor cells, can effectively promote apoptosis of the tumor cells, and has development and application potential as an anti-tumor drug.

The invention discloses a fusion membrane packaged gold-iron core-shell nano diagnosis and treatment preparation as well as a preparation method and application thereof. The preparation takes gold-iron core-shell nanoparticles as a core, and the surface of the gold-iron core-shell nanoparticles is coated with a biomimetic membrane formed by fusion of bacterial outer membrane vesicles and tumor cell membranes. The preparation method comprises the steps of synthesis of the gold-iron nano core, surface functionalization and self-assembly coating of the fusion membrane. The preparation can simultaneously exert photothermal therapy and ferroptosis induction effects under near-infrared light irradiation, effectively initiates tumor cell immunogenicity death, and cooperatively activates dendritic cells and enhances T cell immune response by means of a pathogen related molecular mode carried by the fusion membrane and a tumor related antigen. Experiments show that the preparation can significantly inhibit tumor growth and metastasis, induce long-acting anti-tumor immune memory, and provide a multi-mode synergistic nano platform for tumor immunotherapy.

The invention provides a bacterial outer membrane vesicle based on genetic engineering modification as well as preparation and application thereof, and relates to the technical field of biological medicines. According to the invention, through a genetic engineering technology, a bacterial outer membrane protein ClyA from escherichia coli W3110 is combined with a tumor killing peptide KLAK, and a recombinant plasmid ClyA-KLAK-pGEX-6P-1 for expressing a ClyA-KLAK fusion protein is constructed; the plasmid is transformed into W3110 escherichia coli to realize endogenous expression of the fusion protein, and the engineered outer membrane vesicles C-KLAK-OMVs with anti-tumor activity are successfully prepared. On the basis that the original morphology of the bacterial outer membrane vesicle is reserved, the anti-tumor activity of KLAK is also reserved, migration and invasion of tumor cells HGC27 and MDA-MB-231 can be remarkably inhibited, and apoptosis of the tumor cells HGC27 and MDA-MB-231 is promoted; meanwhile, the medicine loading potential is realized; in addition, the C-KLAK-OMVs also improves the problem of insufficient stability of the KLAK peptide in serum, and provides a new thought and reference for targeted therapy of tumors.

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

The application provides an E. coli outer membrane vesicle targeting TLR2 receptor and a construction method thereof, and relates to the technical field of biological medicine. The application first constructs a ClyA-HLYV fusion protein, and successfully obtains a recombinant plasmid ClyA-HLYV-pGEX-6P-1 stably expressing the fusion protein through genetic engineering technology, and induces endogenous expression of the fusion protein in an E. coli W3110 strain, to prepare a targeted bacterial outer membrane vesicle (HLYV-OMVs) expressing the ClyA-HLYV fusion protein on the surface. The HLYV-OMVs prepared by the application not only retain the specific recognition ability of HLYV to the surface TLR2 receptor of breast cancer cells, but also have the potential to encapsulate drugs, realizing the dual functions of targeted recognition and drug delivery. In addition, the HLYV-OMVs effectively solve the key problem of long-acting time of HLYV single peptide in targeted application, have good stability, significantly accelerate the effect starting speed after HLYV combines with the receptor, and lay an important foundation for efficient targeted treatment of tumors.

The invention provides a bacterial outer membrane vesicle capable of efficiently targeting tumors and a preparation method of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. The target protein PDL1 binding peptide is successfully modified on the surface of the bacterial outer membrane vesicles to prepare the bacterial outer membrane vesicles PDL1-OMVs, the particle size range of the bacterial outer membrane vesicles PDL1-OMVs is 20-250 nm, and the bacterial outer membrane vesicles PDL1-OMVs have an obvious saucer-like double-layer membrane structure and accord with the structural characteristics of the bacterial outer membrane vesicles. According to the PDL1-OMVs provided by the invention, on one hand, the defect that the PD-L1 binding peptide is weak in targeting efficacy is improved, the targeting capability of the PD-L1 binding peptide is remarkably improved, on the other hand, targeting function transformation is realized on the bacterial outer membrane vesicles, and the PDL1-OMVs can realize a specific targeting effect on tumor cells, so that conditions are provided for the PDL1-OMVs serving as a carrier for targeted delivery of tumor drugs.

The invention provides an escherichia coli outer membrane vesicle (OMVs-ClyA-NRP1) with a ClyA-NRP1 fusion protein displayed on the surface as well as a preparation method and application of the escherichia coli outer membrane vesicle, and relates to the technical field of biological medicines. The OMVs-ClyA-NRP1 effectively retains the tumor targeting activity of the NRP1 protein on the basis of maintaining the typical form and structure of the outer membrane vesicles of bacteria, shows excellent targeting binding capacity to breast cancer cells MDA-MB-231, and remarkably accelerates the interaction process of the NRP1 protein and tumor cells. Meanwhile, the vesicle system also has good drug loading potential. According to the invention, the bacterial outer membrane vesicles are modified through a genetic engineering technology, so that the bacterial outer membrane vesicles have targeted binding capacity with breast cancer cells, and a new strategy is provided for targeted therapy of breast cancer.

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

The invention provides an Escherichia coli outer membrane vesicle with a tumor targeting effect and a construction method thereof, and relates to the technical field of engineering transformation of Escherichia coli outer membrane vesicles. According to the invention, the tumor vascular targeting peptide GX1 is modified on the surface of the bacterial outer membrane vesicle, so that the escherichia coli outer membrane vesicle with a tumor targeting effect is successfully obtained. The escherichia coli outer membrane vesicle not only can realize a specific targeting effect on cancer cells, but also remarkably improves the problem of insufficient targeting of the tumor blood vessel targeting peptide GX1. The Escherichia coli outer membrane vesicle provided by the invention is expected to be used as a carrier for targeted delivery of antitumor drugs for further development and research.

The application provides a kind of high-efficiency tumor-targeting bacterial outer membrane vesicle and its preparation method, it is related to biological medicine technical field.The target protein PDL1 binding peptide is successfully modified on the surface of bacterial outer membrane vesicle to prepare bacterial outer membrane vesicle PDL1-OMVs, its particle size range is between 20-250nm, with obvious tea tray like double membrane structure, meet the structural characteristics of bacterial outer membrane vesicle.The PDL1-OMVs provided by the application improves the weak targeting efficiency of PD-L1 binding peptide on the one hand, significantly improves the targeting ability of PD-L1 binding peptide, on the other hand, realizes the targeted functional modification of bacterial outer membrane vesicle, and PDL1-OMVs can realize specific targeting effect on tumor cells, which provides conditions for it as a targeted delivery tumor drug carrier.

The invention belongs to the technical field of biological medicines, and particularly discloses ultrasonic responsive nanoparticles based on gene engineering bacterium outer membrane vesicle-liposome fusion as well as a preparation method and application of the ultrasonic responsive nanoparticles. The nanoparticle OLatCe6 provided by the invention can break through the bottleneck of tumor immunotherapy through a triple synergistic mechanism: (1) immune targeting enhancement: PAMPs rich in OMVs in a fusion shell can be efficiently recognized by antigen presenting cells in a tumor microenvironment, so that the tumor antigen presentation efficiency is remarkably improved; (2) intelligent immune regulation and control: a core slowly-released GM-CSF strongly recruits DCs to a tumor microenvironment and promotes maturation of the DCs, and a persistent immune response hub is established; and (3) sonodynamic-immune synergy: the sonosensitizer embedded in the lipid bilayer explodes ROS under ultrasonic irradiation, accurately induces tumor cells ICD and releases DAMPs, activates deep infiltration of cytotoxic T lymphocytes, and forms an anti-tumor immune positive feedback cycle.

The invention discloses an integrated delivery system and a preparation method and application thereof, and belongs to the technical field of biological medicine. According to the invention, positively charged dendritic macromolecules and plasmids form compound nano-particles, and the compound nano-particles are wrapped by engineered bacterial outer membrane vesicles to form an integrated delivery system. The integrated delivery system can solve the problems that matrix-rich tumors have matrix barriers, gene drugs are difficult to deliver and immune cells are difficult to infiltrate, is simple to prepare, has a series of effects of high tumor accumulation capacity, good biocompatibility and the like, realizes synchronous treatment of three different cell targets of tumor tissues, and has a wide application prospect. The pancreatic cancer immunopotentiator can be used for synergistically attacking a physical barrier, a chemotactic factor barrier and an immunosuppression barrier in a pancreatic cancer matrix, enhancing the lethality of CD8 + T cells and enhancing the immunotherapy effect, and has a good practical application value.

This invention relates to a genetically engineered bacterial outer membrane vesicle and its preparation method. By using in-cell peptides to attach exogenous proteins to the surface of OMVs via peptide bonds, a variety of desired antigens can be conveniently delivered. The reaction conditions are mild, less affected by antigen size, and unlike the SpyCatcher / SpyTag system, the in-cell peptides do not remain in the mature protein after attaching the exogenous protein to the OMV surface. This invention can serve as a universal tool for simultaneously or separately displaying different antigens on the surface of OMVs.

The invention provides a bacterial outer membrane vesicle as well as a preparation method and application thereof. Mediated cell-penetrating peptide and chlorotoxin are co-expressed on the surface of the bacterial outer membrane vesicle. The polypeptide can efficiently pass through BBB and specific targeting tumor cells in vitro and in vivo, and ferroptosis of tumor cells is induced by stimulating IFN-gamma released by CD8 + T cells in vivo, so that growth of glioblastoma is remarkably inhibited. In addition, the IFN-gamma enhances the ferroptosis of the tumor cells caused by the ferroptosis inducer RSL-3 and the erastin. The invention further provides a pharmaceutical composition, the RSL-3 is loaded to the OMV-C-C (at) RSL-3 nano delivery system formed by OMV-C-C, and the OMV-C-C and the RSL-3 show a good synergistic effect in the aspect of inhibiting the growth of glioblastoma.

This invention belongs to the field of biomedical technology and relates to a fusion protein, gene, expression vector, genetically engineered bacteria, and their applications. The fusion protein is derived from the fusion of bacterial outer membrane vesicle protein and human PD-L1, or from the fusion of bacterial outer membrane vesicle protein, human PD-L1, and human Fc protein. Genetically engineered bacteria constructed using the fusion gene provided by this invention can release PD-L1-rich outer membrane vesicles, which can effectively penetrate the lamina propria of the mucosa and regulate inflammation inside and outside the intestine. This genetically engineered bacterium exhibits good biosafety, effectively regulating intestinal flora and metabolism, and improving intestinal barrier function; moreover, it shows good oral administration compliance, which is beneficial for clinical trials.

The invention provides a polypeptide-modified bacterial outer membrane vesicle and application thereof in preparation of a drug for promoting cell growth, and relates to the technical field of biological medicines. According to the invention, a growth promoting polypeptide VTPYGGGGVLLY with a brand new structure is designed on the basis of two micromolecular polypeptides VTPY and VLLY from sea cucumbers, and the engineering bacterial outer membrane vesicle W-VTPVLY OMV with a relatively strong growth promoting effect is prepared by combining the growth promoting polypeptide VTPYGGGGVLLY with bacterial outer membrane protein ClyA by utilizing a genetic engineering technology. The W-VTPVLY OMV provided by the invention has a remarkable promoting effect on HUVEC cell proliferation, migration and revascularization, can play a role in promoting cell proliferation within a short time, and can maintain the proliferation promoting effect for a relatively long time. The W-VTPVLY OMV provided by the invention is expected to become a new medicine for promoting wound regeneration and tissue healing, and provides a new thought and application reference for the fields of tissue engineering and medical materials.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

The present invention relates to the field of bioengineering, and specifically relates to a modified Bordetella pertussis strain in which the mltA gene and pldA gene are mutated, thereby having an increased bacterial outer membrane vesicle (OMV) yield. The present invention further relates to a method for producing the modified Bordetella pertussis strain and a method for producing OMVs by means of the modified Bordetella pertussis strain.

This invention discloses a method for preparing engineered outer membrane vesicles using enzymatic ultrasound technology. The method involves inoculating *E. coli* into LB medium and culturing for 12-16 hours, followed by centrifugation to collect the bacterial cells. The collected bacterial cells are resuspended in lysis buffer and then sonicated for 30-60 minutes to obtain a bacterial solution. After centrifugation, the supernatant is incubated for 30 minutes, followed by centrifugation to separate the precipitate, which is then resuspended in PBS buffer of the same volume as the lysis buffer to obtain a solution containing engineered bacterial outer membrane vesicles. The lysis buffer is prepared by dissolving sorbitol, sodium chloride, EDTA, and lysozyme in Tris-HCl buffer at pH 7.4. This method of preparing engineered outer membrane vesicles using non-genetically engineered strains solves the problems of complex preparation processes, high costs, and inconsistent product quality in existing methods. The obtained engineered outer membrane vesicles can be used as medical preparations for the development of agents to control sporozoites in the Litopenaeus vannamei aquaculture industry.

The invention provides a bacterial outer membrane vesicle based on acid-sensitive peptide labeling as well as a preparation method and application thereof, and relates to the technical field of engineering bacterial outer membrane vesicles. According to the invention, the ClyA-pHLIP fusion protein is designed and synthesized, and the pHA-W3110OMV capable of stably expressing the ClyA-pHLIP fusion protein is successfully obtained by utilizing a genetic engineering technology. The pHA-W3110OMV effectively solves the problem that pHLIP is easy to gather in an acid environment, has better stability and solubility, and provides conditions for the pHLIP to stably play a targeting effect. Meanwhile, the pHA-W3110OMV not only retains the characteristic of targeting tumor cells in an acidic environment, but also realizes the characteristic of targeting tumor cells in a non-acidic environment. Under different pH conditions, the pHA-W3110OMV has relatively high targeting tracing efficiency on tumor cells, can realize qualitative and quantitative detection on the tumor cells in peripheral blood, and has application potential in the aspects of circulating tumor cell detection and tumor primary and metastatic location.

The application discloses an X-ray activated tumor immune metabolism regulation and pyroptosis synergistic bacteria outer membrane vesicle and a preparation method and application thereof, and belongs to the technical field of biotechnology.The application introduces an azido group on the surface of the bacteria outer membrane vesicle through metabolic sugar engineering technology, modifies PEG, a singlet oxygen sensitive linkage and an immune metabolism regulator on the surface of the bacteria outer membrane vesicle in sequence through a click chemistry reaction, and further modifies an X-ray sensitive drug on the bacteria outer membrane vesicle, generates singlet oxygen by irradiating the tumor site with X-rays, causes the singlet oxygen sensitive linkage to break, responsively releases an IDO inhibitor, effectively blocks T cell inhibition induced by high expression of IDO after radiotherapy and restores strong T cell response, reverses the tumor immunosuppressive microenvironment caused by radiotherapy, and simultaneously induces pyroptosis of tumor cells by lipopolysaccharide on the bacteria outer membrane vesicle, further activates the immune response of the body and enhances the radiotherapy effect.

The invention provides engineering C-NGR-OMVs for targeting tumors and a preparation method of the engineering C-NGR-OMVs, and relates to the technical field of engineering bacterial outer membrane vesicles. According to the invention, the engineering C-NGR-OMVs which can stably express fusion protein ClyA-NGR and has a complete bacterial outer membrane vesicle structure and is targeted to tumor is successfully prepared by utilizing a genetic engineering technology. The C-NGR-OMVs provided by the invention can realize a specific targeting effect on tumor cells, the defect that targeting peptide NGR is easy to degrade is improved by utilizing the structural characteristics of bacterial outer membrane vesicles, and the C-NGR-OMVs have relatively good stability in serum and have a more prominent targeting effect on tumor cells compared with the targeting peptide NGR. The invention provides a novel drug nano-delivery carrier for realizing targeted delivery of drugs for treating tumors.

The invention belongs to the technical field of microbial fermentation. The invention provides an application of an outer membrane vesicle of a bacterial strain in preparation of a bacterial agent for inhibiting or killing cryptococcus neoformans. The bacterial strain is stenotrophomonas maltophilia CGMCC (China General Microbiological Culture Collection Center) NO.1. 1788. The invention further provides a preparation method of the bacterial strain. The strain outer membrane vesicles provided by the invention can effectively inhibit the lung cryptococcus neoformans infection.

The application discloses a macrophage-loaded nanocomposite anti-tumor targeted drug delivery system and a preparation method and application thereof. The drug delivery system is formed by loading a Toll-like receptor agonist, a photothermal response agent, a phospholipid and cholesterol into a liposome nanoparticle, coating a bacterial outer membrane vesicle on the outer surface of the drug-loaded liposome nanoparticle to form a drug-loaded nanocomposite, and loading the drug-loaded nanocomposite into macrophages through co-incubation. The system of the application uses macrophages and liposomes as carriers, combines immunotherapy and combined phototherapy to improve the immunotherapy effect by inducing immunogenic cell death caused by the photothermal effect, and further promotes the recruitment and accumulation of macrophages through the regulation of the inflammatory tumor microenvironment, generates a positive feedback cycle, and effectively improves the tumor immunosuppressive microenvironment and inhibits tumor growth and metastasis.

This invention relates to the field of biomedical technology, and more particularly to a tumor vaccine based on bacterial outer membrane vesicles and tumor-associated glycoantigens, its preparation method, and its application. The tumor vaccine provided by this invention induces increased levels of IL-6 and TNF-α secretion in RAW 264.7 and DC 2.4 cells in vitro, promoting phagocytosis and maturation; in vivo, it induces the maturation of T cells and DC cells in the spleen and lymph nodes, significantly inhibiting tumor growth. The tumor vaccine achieves stable antigen loading, induces a strong immune response, significantly inhibits tumor growth, and demonstrates good efficacy and safety in mouse models.

The invention provides an engineered bacterium outer membrane vesicle displaying 4N1K peptide on the surface and a preparation method and application thereof, and relates to the technical field of biological medicine. According to the present invention, the ClyA-4N1K fusion protein is firstly designed, the prokaryotic vector for expressing the ClyA-4N1K protein is constructed through the gene engineering technology, and the ClyA-4N1K fusion protein is displayed on the surface of the bacterial outer membrane vesicle so as to successfully prepare the engineering bacterial outer membrane vesicle W-4N1K OMV; the W-4N1K OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells, and can remarkably promote apoptosis of the tumor cells. Besides, the W-4N1K OMV obviously improves the problem of insufficient stability of 4N1K peptide, shows more excellent anti-tumor effect and serum stability compared with 4N1K single peptide, and obviously enhances the migration and invasion inhibition effect on tumor cells. The W-4N1K OMV provided by the invention has a wide application prospect in the field of research and development of anti-tumor treatment drugs.